AL-S Pharma AG is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TTVM Life Science Innovation I L.P. and Neurimmune. AL-S Pharma plans to begin clinical development in 2018. Once cleared for clinical development by regulatory authorities, the AL-S Pharma compound will be tested in ALS patients.
AL-S Pharma is led by an experienced management team and the Board of Directors comprises Guy Rouleau, director of McGill University’s Montreal Neurological Institute (MNI) and Hospital, Chair Department of Neurology and Neurosurgery, McGill University , Hubert Birner, Managing Partner, TVM Capital Life Science, Munich, Marc Riviere, General Partner, TVM Capital Life Science, Montreal, Roger M. Nitsch (President of Neurimmune and Professor at University of Zurich, Institute for Regenerative Medicine) and Jan Grimm (CSO and Board Member of Neurimmune).
Neurimmune is a biopharmaceutical company dedicated to the development of unique classes of human therapeutic antibodies for the treatment and prevention of important human diseases with a high unmet medical need. Established in 2006 as a spin-off of the University of Zurich, Switzerland, Neurimmune has rapidly grown into a leader in the field of recombinant human monoclonal antibody therapeutics.